# [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Source: https://onco.cc/trials/nct05619016/  
OnCo record `nct05619016` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HER2 PET in Breast cancer and HER2-positive gastric cancer, run by Karolinska University Hospital, with a status the registry has not verified recently.

## Summary

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors is a phase 2 interventional study registered as NCT05619016 by Karolinska University Hospital, with 72 participants planned, started 2022-11-23 and due to reach its primary completion in 2025-12-31. Interventions recorded: [68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2 expression. Conditions recorded: Esophageal Neoplasms, Gastric Neoplasms Malignant, Breast Cancer, HER2-positive Gastric Cancer.

Linked to the technology HER2 PET because the registry names it ("her2 pet") among its interventions and Breast cancer and HER2-positive gastric cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05619016
- Phase: 2
- Setting: Phase II Study of [68Ga]Ga-ABY-025 PET for Non-invasive Quantification of HER2-status in Solid Tumors
- Sponsor: Karolinska University Hospital
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT05619016: https://clinicaltrials.gov/study/NCT05619016

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/)
- technologies: [HER2 PET](https://onco.cc/technologies/her2-pet/)

---
JSON: https://onco.cc/api/v1/entities/nct05619016.json